The path from idea to market is a long and challenging one at the best of times. When you're dealing with medical technologies, it's even more complex. Learn from a panel of experts who've been in the trenches turning medical innovations into business success stories.

Armond Balbon, Partner & Managing Director, Bloom Burton & Co. ( – Armond is the scientific and legal due diligence expert at Bloom Burton & Co. Prior to joining Bloom Burton, he was a member of the Dundee Securities Healthcare and Biotechnology Investment Banking Group. From 2001-2003, Armond was a scientific advisor in the life sciences group of a patent law firm in New York City, where he prosecuted patents in technologies, including small molecule drugs, antibodies, molecular assays, protein chemistry, human cardiovascular diseases, AIDS, Alzheimer’s disease, and neurodegenerative diseases. In addition, Armond has consulted with clients regarding current FDA regulations and filing requirements for generic drugs and medical devices.

Diana Pliura, Entrepreneur in Residence, Health Technology Exchange ( – In her 25 years working in pharma/biotechnology, Diana has experience in advancing therapeutics products through all stages of development, from discovery and target identification, to manufacturing, technology transfer, and early to late stage clinical development. She has helped secure over $100 million in equity financing from private and public capital markets, and has assisted companies through acquisitions, partnerships and IPOs. Currently, Diana is entrepreneur in residence with Health Technology Exchange, a leading resource and catalyst for accelerating growth of Ontario’s medical and assistive technologies cluster. Previously, Diana served as executive vice president at YM BioSciences Inc., founding CEO of DELEX Therapeutics Inc., company creator of the Eastern Technology Seed Investment Fund, and vice president of research at Hemosol Inc.

George Adaniya, CEO, Concert Medical ( – George is a serial entrepreneur who has founded 12 companies, of which he sold three and had two go public, including Andover Controls, where he was co-founder. His career spans three diverse markets: medical devices, aerospace, and industrial controls. George’s leadership and contributions range from technical (patents) to managerial (strategic and operational) to sales and marketing activities.

Bob Bechard – Bob is a consultant in the areas of portfolio management, strategic planning, and fundraising, with over 20 years experience in banking and venture capital. Formerly, he worked for RBC Capital Partners as a managing partner, and as an investment manager with Sofinov, a venture capital fund and subsidiary of the Caisse de Depot et Placement du Quebec, focusing on life sciences investments. Bob has played an active role as a director with numerous private and public biotechnology and medtech companies, and has worked on advisory committees of various US and Canadian biotechnology funds.

Panel moderator – Stephen Hartlen, Interim President & CEO, Innovacorp

Thursday, January 20, 2011
8:45 am - 10:00 am
Harbourview Boardroom
Innovacorp - BioScience Enterprise Centre
1721 Lower Water Street, Halifax, NS

Please RSVP to Samantha Mosley at by Tuesday, January 18, 2011.

As always, these gatherings are intended for Innovacorp clients and affiliates. However, if space allows, we welcome special guests. If you’d like to join us, email us and we’ll let you know about space availability.